Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen

Carcinogenesis

Volumn 18, Issue 11, 1997, Pages 2209-2215

  Martin, Elizabeth A ^a   Carthew, Philip ^a   White, Ian N H ^a   Heydon, Robert T ^a   Gaskell, Margaret ^a   Mauthe, Robert J ^b   Turteltaub, Kenneth W ^b   Smith, Lewis L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; PHENOBARBITAL; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DOSE RESPONSE; DRUG LIVER LEVEL; FEMALE; ISOTOPE LABELING; LIVER LEVEL; LIVER TUMOR; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RATS; TAMOXIFEN;

EID: 0031418207     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.11.2209     Document Type: Article

References (30)

1. Riley, D., Baum, M., Macintyre, J. et al. (1992) The effect of adjuvant tamoxifen - the latest results from the cancer-research-campaign adjuvant breast trial. Eur. J. Cancer, 28A, 904-907.
2. Powles, T.J. (1992) The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet, 340, 1145-1147.
3. Carthew, R. Martin, E.A., White, I.N.H., De Matteis, R. Edwards, R.E., Dorman, B.M., Heydon, R.T. and Smith, L.L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res., 55, 544-547.
4. Williams, G.M. Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
5. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T (1993) Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
6. Hirsimaki, P., Hirsimaki, Y., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver - a 1-year study with 2 antiestrogens. Arch. Toxicol., 67, 49-54.
7. 32P-post-labelling in three rat stains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis, 16, 1299-1304.
8. Carthew, P., Nolan, B.M., Edwards, R.E. and Smith, L.L. (1996) The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett., 106, 163-169.
9. Tucker, M.J., Adams, H.K. and Patterson, J.S. (1984) Tamoxifen. In Laurence, D.R., McLean, A.E.M. and Weatherall, M (eds) Safety Testing of New Drugs. Academic Press, New York, pp. 125-161.
10. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
11. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
12. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2089-2094.
13. Lim, C.K., Chow, L.C.L., Yuan, Z.X. and Smith, L.L. (1993) High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. Biomed. Chromatog., 7, 311-314.
14. Gupta, R.C. (1984) Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl Acad. Sci. USA, 81, 6943-6947.
15. Turteltaub, K.W., Vogel, J.S., Frantz, C.E. and Fultz, F. (1993) Studies on DNA adduction with heterocyclic amines by accelerator mass spectrometry: a new technique for tracing isotope-labelled DNA adduction. In Phillips, D.H., Castegnaro, M. and Bartsch, H. (eds) Postlabeling Methods for Detection of DNA Adducts. IARC, Lyon, France, pp. 293-301.
16. Robinson, S.P. Langan-Fahey, L., Johnson, D.A. and Jordan, V.C. (1991) Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos., 19, 36-43.
17. Lim, C.K., Yuan, Z., Lamb, J.H., White, I.N.H., De Matteis, F. and Smith, L.L. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis, 15, 589-593.
18. Fromson, J.M., Pearson, S. and Bramah, S. (1973) The metabolism of Tamoxifen *(ICI 46,476) Part I: in laboratory animals. Xenobiotica, 3, 693-703.
19. McCague, R., Parr, I.B., Leclercq, G., Leung, O.T. and Jarman, M. (1990) Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem. Pharmacol., 39, 1459-1465.
20. Martin, E.A., Turteltaub, K.W., Mauthe, R., White, I.N.H., Styles, JA. and Smith, L.L. (1996) Toremifene, unlike tamoxifen, is not genotoxic in rat liver. Toxicologist, 30, 233.
21. Smith, L.L., White, I.N.H. and Gant, T.W. (1994) Increased clearance of tamoxifen and its metabolites in rat liver correlates with an increased expression of P-glycoprotein. Toxicologist, 14, 403.
22. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J., Hardcastle, I.R., Poon, G.K., Keogh, A. and Strain, A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
23. Dasardhi, L. and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
24. Osborne, M.R., Hardcastle, I.R. and Phillips, D.H. (1997) Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis, 18, 539-543.
25. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. and Randerath, K. (1996) Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.
26. Walker, V.E., Fennell, T.R., Upton, P.B., Skopek, T.R., Prevost, V., Shuker, D.E.G. and Swenberg, J.A. (1992) Molecular dosimetry of ethylene oxide: formation and persistence of 7-(2-hydroxyethyl)guanine in DNA following repeated exposures of rats and mice. Cancer Res., 52, 4328-1334.
27. IARC (1996) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 66. Some Pharmaceutical Drugs. IARC, Lyon, France.
28. 32P-postlabelled DNA-adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
29. Carmichael, P.L., Ugwumadu, A.H.N., Neven, P., Hewer, A. J., Poon, G.K. and Phillips, D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
30. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.